Mean (Standard Deviation) Thiopurine Pharmacologic Parameters by Dose Intensity Quartiles and TPMT Phenotype in Patients Who Completed 120 Weeks of Therapy
| Parameter . | Quartile . | Wild-Type n = 124 . | Heterozygote n = 16 . | Mutant n = 2 . |
|---|---|---|---|---|
| RBC TGN (pmol/8 · 108RBCs) | <25th 25th-75th >75th | 447 (172) 390 (164) 413 (168) | 1,026 (212) 754 (409) 499 (338) | 1,328 (42) — — |
| Dose intensity for 6MP | <25th 25th-75th >75th | 73% (6) 88% (4) 100% (16) | 38% (24) 76% (8) 83% (19) | 19% (10) — — |
| Proportion of weeks with no 6MP | <25th 25th-75th >75th | .24 (.05) .12 (.04) .07 (.03) | .24 (.08) .20 (.03) .15 (.12) | .16 (6) — — |
| Average weekly 6MP dose (mg/m2/wk), including only those weeks that 6MP was given | <25th 25th-75th >75th | 504 (35) 523 (5) 561 (82) | 270 (198) 494 (42) 507 (78) | 120 (69) — — |
| Parameter . | Quartile . | Wild-Type n = 124 . | Heterozygote n = 16 . | Mutant n = 2 . |
|---|---|---|---|---|
| RBC TGN (pmol/8 · 108RBCs) | <25th 25th-75th >75th | 447 (172) 390 (164) 413 (168) | 1,026 (212) 754 (409) 499 (338) | 1,328 (42) — — |
| Dose intensity for 6MP | <25th 25th-75th >75th | 73% (6) 88% (4) 100% (16) | 38% (24) 76% (8) 83% (19) | 19% (10) — — |
| Proportion of weeks with no 6MP | <25th 25th-75th >75th | .24 (.05) .12 (.04) .07 (.03) | .24 (.08) .20 (.03) .15 (.12) | .16 (6) — — |
| Average weekly 6MP dose (mg/m2/wk), including only those weeks that 6MP was given | <25th 25th-75th >75th | 504 (35) 523 (5) 561 (82) | 270 (198) 494 (42) 507 (78) | 120 (69) — — |